ADRXADARx Pharmaceuticals
临床阶段生物技术公司，专注开发靶向肝脏的siRNA疗法治疗多种疾病。
$17发行价
$447M融资额
$19.35首日收盘
17.29%首日表现
临床阶段生物技术公司，专注开发靶向肝脏的siRNA疗法治疗多种疾病。
公司简介（来源：StockAnalysis）
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention wit...
51CFO 判断：需深度理解biotech资本循环、临床管线估值建模、FDA/SEC双轨披露节奏及研发费用精细化管控。
管理层与创始团队详情以 SEC 招股书披露为准
你的公司需要这样的 CFO 吗？
51CFO 是专注美股市场的投行团队：赴美 IPO、借壳上市、壳公司买卖、SPAC 与 De-SPAC、SEC 申报与上市后再融资，从架构到敲钟一条龙操盘。免费 30 分钟上市路径诊断，24 小时内回复。
预约咨询